Authors

The Ohio State University Comprehensive Cancer Center

Latest:

Ohio State Recruits Top Oncologist to Expand Cell Therapy Program, Lead Bone Marrow Transplant Services

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute has recruited Marcos J. de Lima, MD, to lead its Blood and Marrow Transplant and Cellular Therapy programs, two key leadership positions within central Ohio’s only National Cancer Institute-designated comprehensive cancer center and largest freestanding hospital.

Emil Lou, MD, PhD, FACP

Latest:

Dr Lou on the Rationale for Evaluating CISH Knockout TILs Using CRISPR-Cas9 Gene Editing in Metastatic GI Cancers

Emil Lou, MD, PhD, FACP, discusses the rationale for evaluating CISH knockout TILs using CRISPR-Cas9 gene editing in metastatic GI cancers.

Geoffrey B. Pelz, MD

Geoffrey B. Pelz, MD, is a thoracic surgeon in the Hackensack University Medical Group at the Hackensack University Medical Center in New Jersey.

Latest:

Dr Pelz on the Role of Minimally Invasive Surgical Techniques in Lung Cancer

Geoffrey B. Pelz, MD, discusses the role of minimally invasive surgical approaches for the treatment of patients with lung cancer.

Melinda Krigel

Latest:

UCSF Prostate Cancer Program Awarded SPORE Grant by National Cancer Institute

Researchers will investigate aggressive prostate cancer from a mechanistic, biomarker and therapeutic perspective.

Krina K. Patel, MD, MSc

Krina K. Patel, MD, MSc, is an associate professor in the Department of Lymphoma/Myeloma in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center.

Latest:

Dr Patel on the Efficacy of Anitocabtagene Autoleucel in R/R Multiple Myeloma

Krina K. Patel, MD, MSc, discusses the efficacy of anitocabtagene autoleucel in relapsed/refractory multiple myeloma from the iMMagine-1 trial.

Kevin Zarrabi, MD

Latest:

Dr Zarrabi on Questions Regarding the Use of Triplet Therapy in Prostate Cancer

Kevin Kayvan Zarrabi, MD, MS, FACP, discusses remaining questions regarding treatment consisting of triplet therapy in patients with metastatic castration-sensitive prostate cancer.

Susan Faye Dent, MD

Latest:

Dr. Dent on the Clinical Implications of the MONALEESA-2 Trial in HR+/HER2- Breast Cancer

Susan Faye Dent, MD, discusses the clinical implications of the phase 3 MONALEESA-2 trial in hormone receptor–positive, HER2-negative breast cancer.

Mary B. Beasley, MD

Latest:

Harnessing the Ability to Target NRG1 Fusions in NSCLC, Pancreatic Cancer

Mary B. Beasley, MD, discusses the prevalence of NRG1 fusions in non–small cell lung cancer and pancreatic cancer.

Martine Extermann, MD, PhD

Latest:

Dr. Extermann on the Significance of Novel Treatment Options in HER2+ Breast Cancer

Martine Extermann, MD, PhD, discusses the significance of novel treatment options in HER2-positive breast cancer.

Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University

Latest:

Novel Targeted Therapies Under Investigation in Biliary Tract Cancers

Comprehensive insight on novel targeted agents under investigation in the setting of biliary tract cancers.

John L. Hays, MD, PhD

Latest:

Dr Hays on Unmet Needs in CRC

John L. Hays, MD, PhD, discusses unmet needs for patients with colorectal cancer and future directions for research in this disease.

Shravan Kandula, MD

Latest:

Clinical Scenario: Metastatic EBV-Positive NPC

The panel provides clinical insights on the treatment of a patient with metastatic EBV-positive nasopharyngeal carcinoma.

Samuel Cytryn, MD

Latest:

Immunotherapy's Effect on the Upper GI Cancer Treatment Paradigm

Samuel Cytryn, MD, and David B. Zhen, MD, discuss how immunotherapy has affected the treatment paradigm for upper gastrointestinal cancers.

Wesley J. Talcott, MD, MBA

Latest:

Dr Talcott on Treatment De-Escalation in Elderly Patients With Breast Cancer

Wesley J. Talcott, MD, MBA, discusses the importance of de-escalating therapy in patients with breast cancer, highlighting use of personalized treatment approaches.

Lakshmi Rajdev, MD, MS

Latest:

Dr. Rajdev on Detecting HER2 Positivity in GI Cancer

Lakshmi Rajdev, MD, MS, discusses detecting HER2 positivity in patients with gastrointestinal cancers.

Nusrat Jahan, MD

Nusrat Jahan, MD, is an assistant professor of medicine – hematology & oncology at the O’Neal Comprehensive Cancer Center at The University of Alabama at Birmingham.

Latest:

Dr Jahan on the Role of T-DXd in HR+/HER2-Low Metastatic Breast Cancer

Nusrat Jahan, MD, explains the role of T-DXd as the first cytotoxic therapy in patients with HR-positive/HER2-low or -ultralow breast cancer.

Tarita O. Thomas, MD, PhD

Latest:

Closing Thoughts and Key Takeaways on Small Cell Lung Cancer

In a forward-looking discussion, Ticiana Leal, MD; Anne Chiang, MD, PhD; Afshin Dowlati, MD; and Tarita O. Thomas, MD, PhD, offer their concluding insights on the evolving landscape of clinical trials and the future directions of small cell lung cancer (SCLC) treatment, highlighting promising areas of research and potential breakthroughs that may shape the management of this challenging disease in the years to come.

Viktor Grünwald, MD, PhD

Latest:

Dr Grünwald on Examining Progression Patterns for Lenvatinib Plus Pembrolizumab in Advanced RCC

Viktor Grünwald, MD, PhD, on patterns of progression and subsequent therapy for patients with advanced RCC treated during the phase 3 CLEAR trial.

Michal F. Segal, RN

Latest:

Closing Thoughts on Evolving Antibody-Drug Conjugate Landscape

The expert panel concludes the program with key takeaways and closing thoughts on the evolving antibody-drug conjugate space.

Cristina Lopez-Peñalver, MD

Latest:

Reviewing Best Practices in the Surgical Management of Breast Cancer: Post-Surgery Outcomes in Stage IV Disease

In this final episode of OncChats: Reviewing Best Practices in the Surgical Management of Breast Cancer, Gladys Giron, MD, FACS, and Cristina Lopez-Peñalver, MD, shed light on clinical outcomes following surgery of the primary tumor in patients with stage IV breast cancer.